Open Access
Med Sci (Paris)
Volume 35, Number 8-9, Août–Septembre 2019
Page(s) 629 - 631
Section Le Magazine
Published online 18 September 2019
  1. Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909 ; 5 : 273–290. [Google Scholar]
  2. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 1943 ; 3 : 326–333. [Google Scholar]
  3. Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 1953 ; 13 : 835–837. [Google Scholar]
  4. Burnet FM. Immunological surveillance. Oxford: Pergamon Press, 1970. [Google Scholar]
  5. Shankaran V, Ikeda H, Bruce AT, et al. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001 ; 410 : 1107–1111. [CrossRef] [PubMed] [Google Scholar]
  6. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002 ; 3 : 991–998. [CrossRef] [PubMed] [Google Scholar]
  7. Gasser S, Raulet DH. The DNA damage response arouses the immune system. Cancer Res 2006 ; 66 : 3959–3962. [Google Scholar]
  8. Rosenthal R, Cadieux EL, Salgado R, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 2019 ; 567 : 479–485. [CrossRef] [PubMed] [Google Scholar]
  9. Carbone DP, Reck M, Paz-Ares L, et al. First-line Nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 2017 ; 376 : 2415–2426. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.